• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAR

PARADIGM BIOPHARMACEUTICALS LIMITED.. - News & Media

7.79% ! 35.5¢
Market Cap $141.0M  !
Healthcare Biotechnology
Add to My Watchlist

Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug... Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs.More

Corporate Spotlight

Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs.
View the full Corporate Spotlight arrow Created with Sketch.

PAR - close to a cure for osteoarthritis?

Articles & Videos

Paradigm unlocks $40M loan – and sees a 75cps price not far away

Paradigm Biopharmaceuticals (ASX:PAR) shares were up nearly +25% in morning trades as the company unveiled a loan of around $41 million to advance its osteoarthritis clinical investigations.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from thr...

01 Jul 2025 11:42 (AEST)

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Paradigm Biopharmaceutical (ASX: PAR) has opened the purse strings to pick up Proteobioactives Pty Ltd, which has been working on Pentacoxib, an early-stage oral candidate for minor to mild osteoarthritis.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest hea...

27 Jun 2025 12:33 (AEST)

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

Paradigm Biopharmaceuticals (ASX:PAR) has acquired the exclusive global rights to develop @ and, of course, commercialise @ a novel oral combination of PPS and a COX-2 inhibitor designed to treat osteoarthritis and pains.Listen to the HotCopper podcast for in-depth discussions and insights on all...

26 Jun 2025 11:41 (AEST)

Paradigm activates first Aus site for osteoarthritis drug trials

Paradigm Biopharmaceuticals Ltd has opened its first Australian site as part of a trial to assess injectable pentosan polysulfate sodium

03 Jun 2025 12:08 (AEST)

This stock could have something close to a cure for osteoarthritis. Don’t let it hide under your nose

Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.In the background, Paradigm also has a rare disease clinal asset for Mucopolysaccharidosis (MPS) and early-stage data for acute respiratory d...

21 May 2025 08:34 (AEST)

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Paradigm has confirmed it will use a twice weekly dosage of 2mg/kg injectable pentosan polysulfate sodium in its Phase 3 trial.

18 Sep 2024 09:42 (AEST)

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to Phase III of its osteoarthritis 'program.'

19 Apr 2024 10:14 (AEST)

Paradigm Biopharma tests show reverse knee degradation in osteoarthritis patients

Paradigm Biopharma (ASX:PAR), which is investigating the use of iPPS in osteoarthritis, reported that patients have experienced knee cartilage regrowth.

18 Oct 2023 10:43 (AEDT)

Paradigm clocks 1-year trial result showing iPPS osteo pain decrease

Paradigm Biopharma (ASX:PAR) has reported that its year-long trial using iPPS resulted in OA patients reporting decreased pain.

10 Oct 2023 12:35 (AEDT)

Paradigm Biopharmaceuticals' (ASX:PAR) iPPS demonstrates multiple DMOAD signals in phase two study

Paradigm (ASX:PAR) has claimed a trial of its injectable pentosan polysulfate sodium (iPPS) drug showed the treatment may slow disease progression in knee osteoarthritis (OA).

04 Apr 2023 16:47 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
35.5¢ 		Change
-0.030(7.79%) 		Mkt cap ! $141.0M
Open High Low Value Volume
39.5¢ 39.5¢ 35.0¢ $520.2K 1.422M

Buyers (Bids)

No. Vol. Price($)
3 16628 35.0¢
 

Sellers (Offers)

Price($) Vol. No.
36.5¢ 20839 3
View Market Depth
Last trade - 16.10pm 31/07/2025 (20 minute delay) ?
Last
36.0¢ 		  Change
-0.030 ( 7.69 %)
Open High Low Volume
39.0¢ 39.0¢ 35.0¢ 601265
Last updated 15.59pm 31/07/2025 ?
PAR (ASX) Chart

Top Stories

Larvotto hits "go" on Hillgrove Project

Larvotto Resources (ASX:LRV) has ticked 1.6% higher in intra-day trade after hitting @go” on its Hillgrove Antimony-Gold Project near Armidale in northern New South Wales. The board approved a Final Investment Decision (FID) following a fresh injection of capital to fully fu...
Investor education equals superior returns @Investor education can lead to superior returns”. As the founder of The Stock Network, Lel Smits is determined to elevate investor education for all Aussie investors.I caught up with Lel to talk all things investor education, and why investor education is a great activity f...
Sun Silver unveils Maverick Springs assay results Sun Silver (ASX:SS1) has reported antimony assay results from its ongoing re-assay program at its Maverick Springs Silver-Gold Project in Nevada, USA.The latest assays from historical drillhole MR103 returned a broad intercept of 59 metres including antimony grades of 7.8%. A second hole, MR092, ...
Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign Infini Resources’ newly appointed CEO, Rohan Bone joins The Market Online to discuss strategy moving forward. Join the discussion. See what HotCopper users are saying about Infini Resources and be part of the conversations that move the markets.The material provided in this articl...
HotCopper Trends: Final day of quarterlies; Larvotto FID & more Welcome to HotCopper Trends for Thursday 31st of July @ the last day ahead of Washington’s apparent move to un-pause sweeping tariffs. But that’s neither here nor there. (Nor is the fact that this is the last time we should have to deal with a slog of quarterlies, ...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.